MNT "Biogen Idec has just announced its final first year results of the Phase 3 trial of its relapsing-remitting multiple sclerosis drug Plegridy (peginterferon beta-1a). The drug met all primary and secondary endpoints of the trial results indicating that it is very effective at reducing multiple sclerosis (MS) disease activity. "
'via Blog this'
'via Blog this'
No comments:
Post a Comment